Market Overview

RBC Hints At Potential M&A For Kite Pharma

RBC Hints At Potential M&A For Kite Pharma
Related KITE
Gilead Sciences Outlook Brightens; Citi Upgrades
ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More

Michael Yee of RBC Capital Markets reiterated an Outperform rating on Kite Pharma Inc (NASDAQ: KITE) with a price target boosted to $95 from a previous $85.

According to Yee, competition from Novartis AG (ADR)'s (NYSE: NVS) CTL019 CAR-T isn't too concerning as Novartis' prior studies showed a key manufacturing failure rate of 12 percent versus Kite's manufacturing failure rate of just 1 percent.

As noted by STAT, Kite and Novartis are racing to gain approval for their respective gene therapy that turns a patient's own blood cells into "cancer killers."

Yee also noted Novartis' progress is a few quarters behind Kite's while at the same time Novartis cut back its headcount in 2016, which may give Kite the advantage for the time being in a one-on-one comparison.


Yee also argued that if Kite gets approval from the U.S. Food and Drug Administration for fast approval to meet the need of the cancer population, then the question of M&A comes into play.

The prospect of FDA approval could make it more attractive to the likes of Gilead Sciences, Inc. (NASDAQ: GILD) after the company acknowledged that M&A is a priority for 2017. The analyst argued that acquiring Kite would give Gilead exposure to an un-traditional cancer product that will generate revenue growth.

See Also:

There's A Historical Precedent For The Biotech Selloff

Icahn's (Potential) Move Into Biotech

Latest Ratings for KITE

Aug 2017WedbushUpgradesUnderperformNeutral
Aug 2017Canaccord GenuityDowngradesBuyHold
Aug 2017SunTrust Robinson HumphreyDowngradesBuyHold

View More Analyst Ratings for KITE
View the Latest Analyst Ratings

Posted-In: cancer Cancer Stocks Michael YeeAnalyst Color Analyst Ratings Best of Benzinga


Related Articles (GILD + KITE)

View Comments and Join the Discussion!